Bipolar Disorder Therapeutics

World Market Report

MCP-6202

EXECUTIVE ENGAGEMENTS

POOL

6988
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

1118
Interactions with Platform & by Email

PARTICIPANTS

212
Unique # Participated

VALIDATIONS

77
Responses Validated*

COMPANIES

102
Responses Validated*
* Login for a full stack data experience

DATE

FEB 2022

TABLES

117

PAGES

380

EDITION

19

PRICE

USD 5450

CODE

MCP-6202


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

STRONG ACTIVE NICHE TRIVIAL

%

VALIDATED RESEARCH *

S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year


Global Bipolar Disorder Therapeutics Market to Reach US$6.8 Billion by the Year 2026

Bipolar disorder (also manic depression or manic depressive disorder) is a severe double-edged psychiatric illness featuring cyclical mood swings of depression and elation. Bipolar disorder is one of the leading brain diseases causing unusual shift in energy, mood, activity levels, and ability to perform daily activities. Bipolar disorders increase the risk of premature death due to several comorbidities such as diabetes, obesity, and cardiovascular diseases. Bipolar disorder is treated with medication in addition to alternative therapies of electro convulsion, stress reduction and counselling. Global market for bipolar disorder therapeutics maintained growth trajectory during 2020 and 2021 as patient treatment programs remained mostly unperturbed by the pandemic. Patient inflows remained resilient during the pandemic period and care givers maintained their focus on effective treatment regimens for their patients. In countries such as the US, a large increase in anxiety disorders including panic attacks and social anxiety, amongst people was observed which eventually led to increased uptake of treatment and medications for curing the same. Moreover, rising focus of government and healthcare institutes on treating mental health problems is also expected to bode well for the market. With increasing competition in the market and technological developments, researchers are concentrating on first generation antipsychotics to gain better knowledge of their functioning.

Amid the COVID-19 crisis, the global market for Bipolar Disorder Therapeutics estimated at US$5.9 Billion in the year 2022, is projected to reach a revised size of US$6.8 Billion by 2026, growing at a CAGR of 3.1% over the analysis period. Antipsychotic Drugs, one of the segments analyzed in the report, is projected to grow at a 3% CAGR to reach US$3.1 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anticonvulsants segment is readjusted to a revised 3.9% CAGR for the next 7-year period. This segment currently accounts for a 21.8% share of the global Bipolar Disorder Therapeutics market. Generally prescribed to treat schizophrenia, antipsychotic drugs have a wider relevance in managing bipolar disorders. In bipolar care, antipsychotic drugs are highly preferred in treating periods of psychosis during mania or severe depression. Anticonvulsant drugs aid in the treatment of bipolar disorder and in managing the mania associated with bipolar disorder. Widely prescribed anticonvulsant drugs for bipolar disorder treatment include carbamazepine (Equetro), divalproex sodium (Depakote), lamotrigine (Lamictal), topiramate (Topamax), and valproic acid (Depakene).

The U.S. Market is Estimated at $2.6 Billion in 2022, While China is Forecast to Reach $513.9 Million by 2026

The Bipolar Disorder Therapeutics market in the U.S. is estimated at US$2.6 Billion in the year 2022. The country currently accounts for a 44.35% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$513.9 Million in the year 2026 trailing a CAGR of 4.8% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2% and 3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR while Rest of European market (as defined in the study) will reach US$243.7 Million by the end of the analysis period. North America leads the world bipolar disorder therapeutics market, supported by the strong awareness of the disease condition, existence of leading companies, technological developments, presence of a strong healthcare system, and increasing number of bipolar disorder cases in the region. Asia, led by India and China, is expected to emerge to be the market with strong growth mainly on account of rising prevalence of mental disorders, improving awareness regarding bipolar disorders, and increasing investments by leading companies.

New R&D, product approvals and launches are poised to elevate the prospects of bipolar disorder therapeutics market in the coming years. Recent years saw approval for and roll out of high-quality medications for bipolar disorder. Intra-Cellular Therapies, Alkermes plc and Allergan are some of the companies that have received approvals for their bipolar disorder medications in recent years. While Intra-Cellular Therapies and Alkermes bagged approval for their new drugs, Allergan won the approval for expanded use of Vraylar, which originally received regulatory approval in 2015. In December 2021, Intra-Cellular Therapies bagged the U.S. FDA approval for Caplyta (Lumateperone) compound to treat depressive episodes in patients suffering from bipolar I or bipolar II disorder. Caplyta is currently the one-of-its-kind FDA approved drug to treat depressive episodes emerging from bipolar I or II condition in adults as both monotherapy and adjunctive therapy with either lithium or valproate. Licensed from Bristol-Myers Squibb, Lumateperone is a butyrophenone atypical antipsychotic compound originally developed by Intra-Cellular to treat schizophrenia. Intra-Cellular developed Lumateperone under the name Caplyta for Bipolar Depression and other neurological indications. It is expected that Caplyta medication may evolve into a core treatment option for physicians treating the bipolar condition. In June 2021, Alkermes plc received the U.S. FDA approval for LYBALVI™ (olanzapine and samidorphan) for the treatment of adults with bipolar I disorder. The medication is intended for use as a maintenance monotherapy and also to treat manic or mixed episodes as monotherapy or an adjunct therapy with valproate or lithium. An oral atypical antipsychotic to be taken once daily, LYBALVI contains olanzapine, a proven antipsychotic agent, and a new chemical compound, samidorphan. Following the receipt of regulatory approval, Alkermes commercially launched the drug in October, 2021.

Mood Stabilizers Segment to Reach $1.2 Billion by 2026

Mood stabilizers are the psychiatric drugs that aid in controlling the swings between mania and depression. These medications are formulated to decrease the brain activity and are prescribed to restore neurochemical balance. In the global Mood Stabilizers segment, USA, Canada, Japan, China and Europe will drive the 2.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$873.6 Million will reach a projected size of US$1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$104.2 Million by the year 2026, while Latin America will expand at a 3.5% CAGR through the analysis period.

SELECT PLAYERS

AbbVie Inc.; Astellas Pharma Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Gedeon Richter Plc; GlaxoSmithKline Plc; H. Lundbeck A/S; Janssen Pharmaceutica N.V.; Johnson & Johnson Services, Inc.; Novartis International AG; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Validus Pharmaceuticals LLC

SEGMENTS

» Drug Class (Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs, Anti-Anxiety Drugs)

GEOGRAPHIES

» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Spain » Russia » Rest of Europe » Asia-Pacific » Australia » India » South Korea » Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » UAE » Rest of Middle East » Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Bipolar Disorder Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
Bipolar Disorder Therapeutics - A Prelude
Symptoms of Bipolar Disorder
Mood Episode – A Major Symptom
Manic Episode Vs Depressive Episode
Causes of Bipolar Disorder
Types of Bipolar Disorder
Co-morbidities of Bipolar Disorder
Segments
Antipsychotic Drugs
Anticonvulsants
Mood Stabilizers
Anti-Anxiety Drugs
Select Drugs for Bipolar Disorder Treatment by Drug Class
Impact of Covid-19 and a Looming Global Recession
2020 Marked as a Year of Disruption & Transformation
The Never-Ending “Race” Between the Virus & Vaccines Continues. Amidst this Chaotic Battle, Where is the World Economy Heading Now & Beyond?
COVID-19 Impact on Bipolar Disorder Therapeutics Market
Global Market Analysis and Prospects
Bipolar Disorder Therapeutics Market Set to Witness Rapid Growth
Regional Market Analysis
Treatment Analysis
Anti-Psychotics
Anti-Depressants
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Market Gains to Continue Amid Rising Prevalence of Bipolar Disorder
Awareness Programs Augment Prospects
Increasing R&D Activities Drive the Global Bipolar Disorder Therapeutics Market
Technology Advancements Widen Addressable Market
Social Inclusion of People with Mental Illnesses Augurs Well
Online Self-Management Tools Improve Treatment Outcomes
Increasing Product R&D, Approvals & Launches Support Market Expansion
Side Effects of Bipolar Disorder Drugs
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Bipolar Disorder Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Mood Stabilizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Mood Stabilizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Mood Stabilizers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Antidepressant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Anti-anxiety Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Anti-anxiety Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anti-anxiety Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
UNITED STATES
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
USA Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
CANADA
Canada Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
JAPAN
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Japan Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
CHINA
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
China Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
EUROPE
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Europe Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Bipolar Disorder Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
FRANCE
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
France Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
GERMANY
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Germany Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
ITALY
Italy Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
UNITED KINGDOM
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
UK Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
SPAIN
Spain Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
RUSSIA
Russia Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Bipolar Disorder Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
AUSTRALIA
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
Australia Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
INDIA
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
India Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
India Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
SOUTH KOREA
South Korea Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
LATIN AMERICA
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
Latin America Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Latin America Historic Review for Bipolar Disorder Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027
Latin America Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
ARGENTINA
Argentina Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
BRAZIL
Brazil Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
MEXICO
Mexico Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
REST OF LATIN AMERICA
Rest of Latin America Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
MIDDLE EAST
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
Middle East Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Middle East Historic Review for Bipolar Disorder Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027
Middle East Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
IRAN
Iran Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
ISRAEL
Israel Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
SAUDI ARABIA
Saudi Arabia Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
UNITED ARAB EMIRATES
UAE Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
REST OF MIDDLE EAST
Rest of Middle East Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
AFRICA
Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
Africa Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2012, 2021 & 2027
Total Companies Profiled: 102

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com